SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2056-5968
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants ; volume:8 ; number:1 ; day:21 ; month:12 ; year:2022 ; pages:1-13 ; date:12.2022
Cell discovery ; 8, Heft 1 (21.12.2022), 1-13, 12.2022
- Urheber
-
Wang, Junxiang
Li, Kaiyi
Mei, Xinyue
Cao, Jinpeng
Zhong, Jiaying
Huang, Peiyu
Luo, Qi
Li, Guichang
Wei, Rui
Zhong, Nanshan
Zhao, Zhuxiang
Wang, Zhongfang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41421-022-00501-3
- URN
-
urn:nbn:de:101:1-2023030321130648830063
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Junxiang
- Li, Kaiyi
- Mei, Xinyue
- Cao, Jinpeng
- Zhong, Jiaying
- Huang, Peiyu
- Luo, Qi
- Li, Guichang
- Wei, Rui
- Zhong, Nanshan
- Zhao, Zhuxiang
- Wang, Zhongfang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
Delta or Omicron BA.1/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection